Small supernumerary marker chromosomes (sSMC) can appear in a numerically normal ‘basic karyotype’, but also in a numerically abnormal one like a Turner syndrome karyotype (= sSMCT). Here we present 17 new cases with such a mos 45,X/46,X,+mar karyotype. Moreover we reviewed all 512 cytogenetically similar cases available from the literature and supply for the first time data on occurrence, shapes and subgroups of this rare cytogenetic entity. sSMCT are very rare in the common population (1:100,000) – however, they can be observed with a 45- and even 60-times higher frequency in infertile and (develop)mentally retarded patients, respectively. Even though sSMCT derive from one of the gonosomes in >99% of the cases, there are also exceptional reports on sSMCT derived from one of the autosomes. The majority of sSMCT(X) form ring chromosomes, while most sSMCT(Y) are inverted duplicated/isodicentric chromosomes. Although >500 sSMCT are reported, a detailed characterization of the chromosomal breakpoints is only given for a minority. Thus, more cases with detailed (molecular) cytogenetic marker chromosome characterization are needed to provide information on formation and effects of an sSMCT.

1.
Alvarez-Nava F, Soto M, Martinez MC, Prieto M, Alvarez Z: FISH and PCR analyses in three patients with 45,X/46,X,idic(Y) karyotype: clinical and pathologic spectrum. Ann Genet 46:443–448 (2003).
2.
Arnedo N, Nogues C, Bosch M, Templado C: Mitotic and meiotic behaviour of a naturally transmitted ring Y chromosome: reproductive risk evaluation. Hum Reprod 20:462–468 (2005).
3.
Bianco B, Lipay MV, Melaragno MI, Guedes AD, Verreschi IT: Detection of hidden Y mosaicism in Turner’s syndrome: importance in the prevention of gonadoblastoma. J Pediatr Endocrinol Metab 19:1113–1117 (2006).
4.
Binder G, Koch A, Wajs E, Ranke MB: Nested polymerase chain reaction study of 53 cases with Turner’s syndrome: is cytogenetically undetected Y mosaicism common? J Clin Endocrin Metabol 80:3532–3536 (1995).
5.
Crolla JA: FISH and molecular studies of autosomal supernumerary marker chromosomes excluding those derived from chromosome 15: II. Review of the literature. Am J Med Genet 75:367–381 (1998).
6.
Egozcue S, Blanco J, Vendrell JM, Garcia F, Veiga A, et al: Human male infertility: chromosome anomalies, meiotic disorders, abnormal spermatozoa and recurrent abortion. Hum Reprod Update 6:93–105 (2000).
7.
Fujimoto A, Boelter WD, Sparkes RS, Lin MS, Battersby K: Monozygotic twins of discordant sex both with 45,X/46,X,idic(Y) mosaicism. Am J Med Genet 41:239–245 (1991).
8.
Grass FS, Brown CA, Backeljauw PF, Lucas A, Brasington C, et al: Novel ring chromosome composed of X- and Y-derived material in a girl with manifestations of Ullrich-Turner syndrome. Am J Med Genet 93:343–348 (2000).
9.
Gray BA, Bent-Williams A, Wolff DJ, Zori RT: A non-sex chromosome marker in a patient with an atypical Ullrich-Turner phenotype and mosaicism of 46,X,mar/46,XX. Clin Genet 60:73–76 (2001).
10.
Hsu LY: Phenotype/karyotype correlations of Y chromosome aneuploidy with emphasis on structural aberrations in postnatally diagnosed cases. Am J Med Genet 53:108–140 (1994).
11.
Kurosawa K, Harada N, Sosonkina N, Niikawa N, Matsumoto N, Saitoh S: Unmasking 15q12 deletion using microarray-based comparative genomic hybridization in a mentally retarded boy with r(Y). Am J Med Genet A 130:322–324 (2004).
12.
Li MM, Howard-Peebles PN, Killos LD, Fallon L, Listgarten E, Stanley WS: Characterization and clinical implications of marker chromosomes identified at prenatal diagnosis. Prenat Diagn 20:138–143 (2000).
13.
Liehr T: sSMC home page = page on small supernumerary marker chromosomes. http://www.med.uni-jena.de/fish/sSMC/00START.htm (2007).
14.
Liehr T, Weise A: Frequency of small supernumerary marker chromosomes in prenatal, newborn, developmentally retarded and infertility diagnostics. Int J Mol Med 19:719–731 (2007).
15.
Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, et al: Microdissection based high resolution multicolor banding for all 24 human chromosomes. Int J Mol Med 9:335–359 (2002).
16.
Liehr T, Claussen U, Starke H: Small supernumerary marker chromosomes (sSMC) in humans. Cytogenet Genome Res 107:55–67 (2004).
17.
Liehr T, Mrasek K, Weise A, Dufke A, Rodriguez L, et al: Small supernumerary marker chromosomes – progress towards a genotype-phenotype correlation. Cytogenet Genome Res 112:23–34 (2006).
18.
Medlej R, Lobaccaro JM, Berta P, Belon C, Leheup B, et al: Screening for Y-derived sex determining gene SRY in 40 patients with Turner syndrome. J Clin Endocrinol Metab 75:1289–1292 (1992).
19.
Mittwoch U: Sex determination and sex reversal: genotype, phenotype, dogma and semantics. Hum Genet 89:467–479 (1992).
20.
Nagafuchi S, Tamura T, Nakahori Y, Takano K, Nishi Y, et al: The majority of the marker chromosomes in Japanese patients with stigmata of Turner syndrome are derived from Y chromosomes. Hum Genet 89:590–592 (1992).
21.
Nishi MY, Domenice S, Medeiros MA, Mendonca BB, Billerbeck AE: Detection of Y-specific sequences in 122 patients with Turner syndrome: nested PCR is not a reliable method. Am J Med Genet 107:299–305 (2002). Erratum in: Am J Med Genet 113:116–117 (2002).
22.
Ogata T, Matsuo N: Turner syndrome and female sex chromosome aberrations: deduction of the principal factors involved in the development of clinical features. Hum Genet 95:607–629 (1995).
23.
Park JP, Brothman AR, Butler MG, Cooley LD, Dewald GW, et al: Extensive analysis of mosaicism in a case of Turner syndrome: the experience of 287 cytogenetic laboratories. College of American Pathologists/American College of Medical Genetics Cytogenetics Resource Committee. Arch Pathol Lab Med 123:381–385 (1999).
24.
Ramos ES: Turner syndrome: counseling prior to oocyte donation. Sao Paulo Med J 125:112–114 (2007).
25.
Sagi L, Zuckerman-Levin N, Gawlik A, Ghizzoni L, Buyukgebiz A, et al: Clinical significance of the parental origin of the X chromosome in Turner syndrome. J Clin Endocrinol Metab 92:846–852 (2007).
26.
Semerci CN, Satiroglu-Tufan NL, Turan S, Bereket A, Tuysuz B, et al: Detection of Y chromosomal material in patients with a 45,X karyotype by PCR method. Tohoku J Exp Med 211:243–249 (2007).
27.
Shago M, Sgro M, Barozzino T, Antinucci D, Chakraborty P, et al: An active ring X and haploinsufficiency of SHOX contribute to short stature, congenital anomalies, and developmental delay in a female. Am J Med Genet 113:279–285 (2002).
28.
Starke H, Nietzel A, Weise A, Heller A, Mrasek K, et al: Small supernumerary marker chromosomes (SMCs): genotype-phenotype correlation and classification. Hum Genet 114:51–67 (2003).
29.
Stuppia L, Calabrese G, Franchi PG, Mingarelli R, Morizio E, et al: Molecular studies in three patients with isodicentric Y chromosome. Hum Genet 98:691–695 (1996).
30.
Tharapel SA, Wilroy RS, Keath AM, Rivas ML, Tharapel AT: Identification of the origin of ring/marker chromosomes in patients with Ullrich-Turner syndrome using X and Y specific alpha satellite DNA probes. Am J Med Genet 42:720–723 (1992).
31.
Wiktor A, Van Dyke DL: FISH analysis helps identify low-level mosaicism in Ullrich-Turner syndrome patients. Genet Med 6:132–135 (2004).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.